Please assess the completion status of the following clinical trial:

Trial Title: Study of Belimumab Administered Subcutaneously to Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Healthy subjects defined as no clinically relevant abnormalities identified by a detailed medical history, full physical exam, 12-lead electrocardiogram (ECG), and clinical laboratory tests.~* Body weight between 45 to 120 kg (99 to 264 lbs).~* Must agree to use effective contraception throughout the study and for 14 weeks after administration of belimumab.~* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.~Key Exclusion Criteria:~* Pregnant or nursing.~* Test positive for drugs or alcohol or have had a drug or alcohol dependence within the past year.~* Have used any prescription medicines within the past 30 days or herbal/botanical supplements within the past 7 days or anticipate use during the study. May use prescription contraceptives, hormone replacement therapy, and over-the-counter medicines such as antihistamines or nutritional support such as vitamins, minerals, or amino acids.~* Have received a live vaccine within the past 30 days or anticipate receipt of a live vaccine during the study and within 4 months after last injection of belimumab.~* Have a history of an allergic or anaphylactic reaction to drugs, food, or insect bite or sting requiring medical intervention.~* Have a history of allergic reaction to contrast agents or biological medicines.~* Have participated in a clinical trial and received an experimental medicine within the past 60 days.~* Have received treatment with a B cell targeted therapy at any time.~* Have required management of an infection within the past 14 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Belimumab IV 240 mg (Type: ACTIVE_COMPARATOR): None
- Belimumab SC 2 x 120 mg (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 240 mg (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 200 mg (Type: EXPERIMENTAL): None
- Belimumab SC 2 x 120 mg weekly (Type: EXPERIMENTAL): None
- Belimumab SC 1 x 200 mg weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).